Product Description

Formula & Concentration

HEMLIBRA® (emicizumab-kxwh) injection, for subcutaneous use

Manufacturer

Genentech Inc

Indications

HEMLIBRA is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.

Product Options

Package Size

NDC #

Presentation

30 mg

50242-0920-01

Vial

60 mg

50242-0921-01

Vial

105 mg

50242-0922-01

Vial

150 mg

50242-0923-01

Vial

300 mg /2 mL

50242-0930-01

Vial

Shelf Life and Storage

Store HEMLIBRA vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.

Do not freeze. Do not shake.

Prior to administration, if needed, unopened vials of HEMLIBRA may be stored out of and then returned to refrigeration. The temperature and total combined time out of refrigeration should not exceed 30°C (86°F) and 7 days (at a temperature below 30°C [86°F]), respectively.

Once removed from the vial, discard HEMLIBRA if not used immediately. Discard any unused HEMLIBRA.